The Trump administration, perhaps surprisingly, chose to defend the legality of the Inflation Reduction Act’s (IRA’s) drug ...
The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate ...
Topline: Taxpayers spent $74.5 million to help develop the prostate cancer-fighting drug Xtandi, but its sky-high sticker ...
A new study from the USC Schaeffer Center shows that out-of-pocket costs for brand-name medications have increased sharply ...
New federal legislation would regulate an industry that’s been examined by FactFinder. Senator Jerry Moran, R-Kan., is one of ...
Providers are sympathetic to Medicare enrollees’ concerns but don’t agree on their role in helping patients find less costly ...
Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who ...
Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.
Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...
Debate over whether or not the Affordable Care Act, commonly known as Obamacare, worked and how President Trump's executive ...
The latest weight-loss drugs including Ozempic, Wegovy, Mounjaro, and Zepbound have list prices ranging from $900 to $1,500 for a one-month supply. David Ricks, the CEO of Mounjaro and Zepbound ...
“Governor Maura Healey’s proposal, to increase costs for prescription drugs, is absolutely ‘ill’ advised. Healthcare costs in ...